FIBROCELL LIMITED

Company Registration Number:
00705725 (England and Wales)

Unaudited abridged accounts for the year ended 31 March 2023

Period of accounts

Start date: 01 April 2022

End date: 31 March 2023

FIBROCELL LIMITED

Contents of the Financial Statements

for the Period Ended 31 March 2023

Balance sheet
Notes

FIBROCELL LIMITED

Balance sheet

As at 31 March 2023


Notes

2023

2022


£

£
Fixed assets
Tangible assets: 3 215 252
Total fixed assets: 215 252
Current assets
Stocks: 275 300
Debtors:   1,441 2,060
Cash at bank and in hand: 10,437 11,257
Total current assets: 12,153 13,617
Creditors: amounts falling due within one year:     (45)
Net current assets (liabilities): 12,153 13,572
Total assets less current liabilities: 12,368 13,824
Provision for liabilities: (497) (648)
Total net assets (liabilities): 11,871 13,176
Capital and reserves
Called up share capital: 252 252
Profit and loss account: 11,619 12,924
Shareholders funds: 11,871 13,176

The notes form part of these financial statements

FIBROCELL LIMITED

Balance sheet statements

For the year ending 31 March 2023 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 04 July 2023
and signed on behalf of the board by:

Name: B A Swift
Status: Director

The notes form part of these financial statements

FIBROCELL LIMITED

Notes to the Financial Statements

for the Period Ended 31 March 2023

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

FIBROCELL LIMITED

Notes to the Financial Statements

for the Period Ended 31 March 2023

2. Employees

2023 2022
Average number of employees during the period 1 1

FIBROCELL LIMITED

Notes to the Financial Statements

for the Period Ended 31 March 2023

3. Tangible Assets

Total
Cost £
At 01 April 2022 42,324
At 31 March 2023 42,324
Depreciation
At 01 April 2022 42,072
Charge for year 37
At 31 March 2023 42,109
Net book value
At 31 March 2023 215
At 31 March 2022 252